Ignite Creation Date:
2024-05-06 @ 8:07 AM
Last Modification Date:
2024-10-26 @ 11:56 AM
Study NCT ID:
NCT02675478
Status:
COMPLETED
Last Update Posted:
2019-02-12
First Post:
2016-02-02
Brief Title:
Phase 1 Study of Quizartinib
Sponsor:
Daiichi Sankyo Co Ltd
Organization:
Daiichi Sankyo
Study Overview
Official Title:
A Phase 1 Open-Label Dose Escalation Study of Quizartinib An Oral FLT3 Inhibitor in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
COMPLETED
Status Verified Date:
2018-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a dose escalation study to evaluate the safety tolerability and pharmacokinetics of quizartinib for Japanese acute myeloid leukemia AML subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None